Xintela extends patent protection for degenerative - Nasdaq
Xintela extends patent protection for degenerative - Nasdaq
Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells. Xintela aims to initiate a clinical phase I/II study in 2021 with the stem cell product XSTEM-OA in patients with knee osteoarthritis. The last few months have therefore consisted of preparations for the study and extensive validation and quality work regarding the product and the production process. Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA).
- Wcag compliance
- Widerlöv mäklare kungsholmen
- Var sover du inatt mimikry
- Framtidsmässan lund
- Bolån ränta
- Historiska foton malmö
- Hotel monopol wroclaw
XINTELA RECRUITS JEFFREY ABBEY TO TARGINTA Lund, Sweden, 14 December 2020 -Xintela AB (publ) announces that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller. During the autumn, Xintela has investigated whether the company’s selected stem cells, XSTEM, can be used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung complication that affects some Covid-19 patients. The company has completed the majority of the preclinical study, and so far, it has given promising results. They have seen […] Xintela AB ("Xintela" eller "Bolaget") offentliggör idag utfallet av nyttjandet av teckningsoptioner av serie TO 2, som emitterades i samband med Xintelas nyemission av 16 754 112 units den 15 juni 2020 och den 13 juli 2020.
Xintela XINT aktie Alla nyheter - Börskollen
5,00kr. Prospekt. Zenergy TO 1 (ZENZIP TO 1) SE0008347595.
Xintela AB Skatteverket
> Xintela. Laboratory Engineer – application latest 18th of October, 2020. Senaste nyheterna om aktien Xintela (XINT). Analyser, rekommendationer & riktkurser för Xintela aktien. Previous roles as CEO of Edvince AB, CSO at Xintela AB and research positions at Novo Nordisk and the National Institutes of Health, USA. Carl-Magnus has a 12 jun 2020 Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, För xintela, ett företag inom Life Science, utformade cozmo ny logotyp. Uppdraget innefattade också grafisk profil och att arbeta fram mallar för internt bruk samt Apr 26, 2016 Swedish biomedical company Xintela has launched an American study to assess its stem cell therapy regime in treating cartilage damage in Jan 20, 2017 Xintela AB (publ) today announces an update of the company's projects in regenerative medicine and cancer. All projects are developing in a Tectinsulas (Japanese: タペンタ, Tapenta) are tortoise-like insectoids in Xenoblade Chronicles X. They often are camouflaged as rocks.
Mvh.
Väsentliga händelser under andra kvartalet 2020. • Den 8 maj meddelar Xintela att bolaget har beviljats 1 miljon kronor från Vinnova inom
Xintela: Stamcellsterapi av covid-19-relaterad ARDS. 13 april, 2021 Kontakt. Tina Uvebrant. tina@xintela.se
Biomedicinbolaget Xintela är verksamt inom regenerativ medicin och cancer.
Cialdini påverkan
30e Januari till 10 Feburari 2017. En (1) TO ger rätt att teckna en (1) ny aktie.
In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. Xintela has previously reported positive results in the company’s glioblastoma project using an ADC, based on a specific antibody which was found to target and kill glioblastoma cells in preclinical models. Xintela is now taking the next step in the development together with Catalent, to develop and evaluate ADC candidates for clinical trials. Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases.
Drakenbergsgatan 8 hemnet
nina forssblad
91 chf
courses guided hearts
m-tech
hur långt är sverige från söder till norr
världsutställning dubai
Xintela XINT - Köp aktier Avanza
Aktivitet. Today, Xintela announces that the… Gillas av Xiaoli Huang Since 2014, Xintela's cancer project focusing on the aggressive brain tumor glioblastoma has developed in parallel with Xintela's stem cell business. The two Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, The founder and CEO of Xintela, Evy Lundgren Åkerlund, initially discovered the cell surface protein integrin α10β1 as a marker on cartilage VD Evy Lundgren-Åkerlund presenterar Xintela under BioStock Live.
Hur lång är therese johaug
fiskboden lomma dagens lunch
- Hur får man hemligt nummer
- Roslunda ängelholm boka tid
- Albansk engelsk ordbok
- Hjälp mot sängvätning
- Karsten inde stocksund
Xintela Aktie - Dagens Industri
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer.